10-Q: Cassava Sciences Pivots to Epilepsy After Alzheimer's Setback

Cassava Sciences reported a net loss of $10.8 million for Q3 2025, discontinuing its Alzheimer's program to focus on TSC-related epilepsy with a new Yale license.

Summary

• Cassava Sciences reported a net loss of $10.8 million for the three months ended September 30, 2025, an improvement from a net loss of $27.9 million in the same period of 2024.
• For the nine months ended September 30, 2025, the company incurred a net loss of $78.4 million, compared to a net income of $3.3 million in the prior year, which included a significant non-cash gain from warrant liabilities.
• Cash and cash equivalents stood at $106.1 million as of September 30, 2025, down from $128.6 million at December 31, 2024.
• Research and development expenses decreased by 78% to $4.0 million for Q3 2025 and by 54% to $22.7 million for the nine months ended September 30, 2025, primarily due to the phase-out of the Alzheimer's disease development program.
• General and administrative expenses decreased by 39% to $7.9 million for Q3 2025 and by 6% to $59.1 million for the nine months ended September 30, 2025, influenced by lower legal costs and severance in 2025 compared to a $40 million SEC-related loss contingency in 2024.
• The company has an accumulated deficit of $483.5 million as of September 30, 2025.
• The Alzheimer's disease development program, including Phase 3 RETHINK-ALZ and REFOCUS-ALZ studies, was discontinued in Q2 2025 after failing to meet co-primary, secondary, and exploratory biomarker endpoints.
• Cassava Sciences has shifted its primary focus to developing simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy, securing exclusive worldwide rights to Yale University's intellectual property for this indication.
• Positive preclinical results for simufilam in a mouse model of TSC-related epilepsy were announced on August 4, 2025, showing attenuated seizure progression.
• An Investigational New Drug (IND) application has been submitted for a proof-of-concept clinical trial of simufilam in TSC-related epilepsy, expected to begin in the first half of 2026.
• The SavaDx diagnostic program was discontinued as of mid-2025.
• A workforce reduction of 10 employees (33%) was implemented on January 7, 2025, incurring $0.4 million in severance costs.
• The SEC investigation was settled on September 26, 2024, with a $40 million civil monetary penalty paid in November 2024.
• A criminal indictment against former scientific collaborator Dr. Hoau-Yan Wang was dismissed with prejudice on October 23, 2025.
• The company has reserved a loss contingency of $31.25 million as of September 30, 2025, for a potential settlement of the Consolidated Securities Action, with advanced settlement discussions underway.

Sentiment

Score: 4

Explanation: The sentiment is cautious. While the company has resolved some significant legal overhangs (SEC settlement, Dr. Wang's indictment dismissal) and pivoted to a new, potentially promising therapeutic area (TSC-related epilepsy) with preclinical data and a Yale license, the complete failure and discontinuation of its primary Alzheimer's program represent a major setback. Ongoing substantial legal liabilities and continued net losses, despite reduced R&D, temper optimism. The new program is very early stage, and future funding needs are acknowledged, indicating continued financial uncertainty.

Positives

• Significant reduction in research and development expenses due to the completion of the Alzheimer's program phase-out, leading to lower cash burn in this area.
• Positive preclinical results for simufilam in a well-accepted mouse model of TSC-related epilepsy, indicating potential efficacy in attenuating seizure progression.
• Secured exclusive worldwide rights to Yale University's intellectual property for simufilam in TSC-related epilepsy, providing a new strategic direction and potential market opportunity.
• Submission of an Investigational New Drug (IND) application for a proof-of-concept clinical trial in TSC-related epilepsy, with initiation expected in the first half of 2026, marks progress in the new therapeutic focus.
• Resolution of the SEC investigation with a $40 million civil penalty paid, removing a significant regulatory overhang.
• Dismissal with prejudice of the criminal indictment against former scientific collaborator Dr. Hoau-Yan Wang on October 23, 2025, eliminates a potential reputational and legal burden.
• Management believes that current working capital is sufficient to meet the company's needs for at least the next 12 months.

Negatives

• Continued net losses, with a net loss of $10.8 million for Q3 2025 and an accumulated deficit of $483.5 million as of September 30, 2025.
• The complete discontinuation of the Alzheimer's disease development program, including two Phase 3 studies (RETHINK-ALZ and REFOCUS-ALZ), due to failure to meet primary and secondary endpoints, represents a major setback for the company's previous lead candidate.
• Cash and cash equivalents decreased by $22.5 million during the nine months ended September 30, 2025, from $128.6 million to $106.1 million.
• A $31.25 million loss contingency has been reserved for a potential settlement of the Consolidated Securities Action, indicating significant ongoing legal liabilities.
• The SavaDx diagnostic program was discontinued as of mid-2025, eliminating another potential product candidate.
• A workforce reduction of 33% (10 employees) was implemented in January 2025, indicating operational restructuring due to program changes.
• Interest income decreased due to lower interest rates and cash balances.
• Expected continuation of net losses from leasing activities due to higher vacancy rates in the company-owned office complex.

Risks

• The company may not be able to obtain additional funding through public or private financing on favorable terms, or at all, which could impact its ability to fund future operations.
• There are no assurances of regulatory and market acceptance for the company's product candidates, including simufilam for TSC-related epilepsy.
• New drug discovery and development is a long, complex, costly, and high-risk process, with no guarantee of success.
• The company relies heavily on third-party contractors for clinical and non-clinical trials and drug supply, and their performance or ability to deliver on time and budget is critical.
• Clinical results from earlier-stage trials may not be indicative of future results from later-stage or larger-scale clinical trials, and do not ensure regulatory approval.
• Disruptions at the FDA, including workforce reductions or inadequate funding, could delay or prevent the timely review and approval of regulatory submissions.
• U.S. government actions regarding drug prices, such as the 'Most-Favored Nation Prescription Drug Pricing' Executive Order, could negatively impact future revenues, margins, and global pricing strategies.
• The outcome of ongoing litigation and government inquiries is inherently uncertain, and legal proceedings can have an adverse impact due to defense and settlement costs, and diversion of management resources.
• The company is unable to predict the outcome or estimate the amount of loss or range of losses that could potentially result from pending shareholder derivative actions and the 2024 Securities Class Action.
• Fluctuations in financial or operating results are expected due to factors like clinical trial enrollment rates and timing of preclinical activities.
• Expenses or incurred costs may increase by material amounts in excess of budgeted amounts due to unexpected cost overruns, imperfect forecasting, or increased scope of activities.
• The company's ability to attract and retain key personnel is crucial for its development programs.
• The sufficiency of the company's cash resources to continue funding operations beyond the next 12 months is not guaranteed.

Future Outlook

Management believes current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months, but the company may seek additional funding through public or private financing in the future. Research and development expenses are expected to decrease in future periods due to the completion of the Alzheimer's program phase-out, partially offset by costs for the new TSC-related epilepsy program. General and administrative expenses are expected to decrease significantly but remain high due to ongoing legal fees and potential settlements. Interest income is projected to decrease due to cash utilization and a lower interest rate environment, while losses from leasing activities are expected to continue due to higher vacancy rates. The company plans to initiate a proof-of-concept clinical study for simufilam in TSC-related epilepsy in the first half of 2026 and continue exploratory preclinical studies.

Management Comments

• Richard J. Barry, President and Chief Executive Officer, and Eric J. Schoen, Chief Financial Officer, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact, and that the financial statements fairly present the financial condition, results of operations, and cash flows.
• The certifying officers concluded that the company's disclosure controls and procedures were effective as of September 30, 2025.

Industry Context

Cassava Sciences, a clinical-stage biotechnology company, is undergoing a significant strategic pivot, discontinuing its Alzheimer's disease program after two Phase 3 failures. This is a common occurrence in the challenging Alzheimer's drug development landscape, where many candidates fail in late-stage trials. The company's new focus on Tuberous Sclerosis Complex (TSC)-related epilepsy represents a shift to a rare disease indication, a strategy often employed by biotechs to target areas with high unmet medical need, potentially less competition, and clearer regulatory pathways (e.g., orphan drug designation). The collaboration with Yale University and the TSC Alliance for preclinical research aligns with industry trends of leveraging academic expertise and patient advocacy groups for rare disease development. The company's acknowledgment of potential impacts from FDA workforce reductions and U.S. drug pricing policies reflects broader industry concerns regarding regulatory and market access environments.

Comparison to Industry Standards

• The failure of simufilam in two Phase 3 Alzheimer's trials is consistent with the high attrition rate observed across the pharmaceutical industry for Alzheimer's drug candidates, where many large and small companies have experienced similar setbacks.
• The pivot to a rare disease like TSC-related epilepsy is a recognized strategy in the biotech sector to pursue indications with smaller patient populations but potentially faster development timelines and higher pricing power, often leading to orphan drug designations.
• The cash burn rate for a clinical-stage biotechnology company, even after discontinuing a major program, is typical, as R&D and G&A expenses remain substantial. The reported cash position of $106.1 million and management's belief of a 12-month runway are within the expected range for companies at this stage, especially those initiating new clinical programs.

Management Changes

Corporate Governance

Legal Proceedings

• **Government Investigations:** The company received subpoenas, a Civil Investigative Demand (CID), and other requests for documents and information from the Department of Justice (DOJ) and document requests from the SEC concerning the research and development of simufilam and SavaDx. The SEC investigation was settled on September 26, 2024, with a final consent judgment entered on October 18, 2024, and a civil monetary penalty of $40 million paid in November 2024. The company continues to cooperate with the DOJ. On October 23, 2025, the criminal indictment against former scientific collaborator Dr. Hoau-Yan Wang was dismissed with prejudice.
• **Securities Class Actions and Shareholder Derivative Actions:** Four putative class action lawsuits (August-October 2021) alleging federal securities law violations were consolidated into the 'Consolidated Securities Action.' The Texas District Court granted class certification on August 12, 2025, which defendants are appealing to the Fifth Circuit Court of Appeals (appeal agreed to be heard on October 21, 2025). The company is in advanced settlement discussions for this action and has reserved a $31.25 million loss contingency as of September 30, 2025. Multiple shareholder derivative actions related to these class actions are currently stayed. A 2024 Securities Class Action (filed December 13, 2024) related to the RETHINK-ALZ Phase 3 results is pending, with a motion to consolidate into the Consolidated Securities Action.
• **CIB Derivative Action:** A shareholder derivative action (filed August 19, 2022) in the Delaware Court of Chancery regarding the 2020 Cash Incentive Bonus Plan was settled, with a Final Order and Judgment entered on January 24, 2025. The company paid $1.0 million in attorneys fees and expenses in February 2025.
• **Anti-SLAPP Lawsuit:** A lawsuit (filed August 6, 2024) in New York asserting claims, including under the New York Anti-SLAPP Law, against the company and two former officers. The company paid approximately $2.5 million in October 2025 for settlement agreements with intervenor plaintiffs and another potential plaintiff.

Related Party Transactions

• Former President and Chief Executive Officer: Received severance compensation of $1.23 million, paid ratably over twelve months following his resignation effective September 13, 2024. A consulting agreement with him was terminated effective January 23, 2025, with de minimis fees paid.
• Former Senior Vice President, Neuroscience (spouse of former President and CEO): Received severance compensation of $0.5 million, paid in quarterly installments over twelve months following her step down on July 16, 2024. A one-year consulting agreement was entered on July 16, 2024, for $500 per hour; $20,000 in fees were incurred during the nine months ended September 30, 2025.
• James W. Kupiec, M.D. (former Chief Medical Officer): Entered into a one-year consulting agreement on June 20, 2025, for a fixed fee of $42,000 for services relating to company manuscripts and publications. $21,000 in fees were incurred during the three months ended September 30, 2025, and $42,000 during the nine months ended September 30, 2025.

Stakeholder Impact

• **Shareholders:** Face continued financial uncertainty due to ongoing net losses, an accumulated deficit, and significant legal liabilities (e.g., $31.25 million loss contingency for securities class action). However, the resolution of the SEC investigation and the dismissal of the indictment against a key collaborator remove some legal overhangs. The strategic pivot to TSC-related epilepsy offers a new, albeit early-stage, potential growth avenue.
• **Employees:** Experienced a workforce reduction of 33% (10 employees) in January 2025. New key hires in scientific and medical roles indicate a restructuring and focus on the new therapeutic area.
• **Customers (potential):** The discontinuation of the Alzheimer's program means no product for that indication. The new focus on TSC-related epilepsy could eventually provide a much-needed treatment for patients suffering from this rare genetic disorder.
• **Creditors:** The company's current cash and cash equivalents are believed to be sufficient for at least the next 12 months, but the acknowledgment of potential future capital raises suggests ongoing reliance on external funding.
• **Regulatory Bodies:** The company has settled a significant SEC investigation and continues to cooperate with the DOJ. It is now engaging with the FDA for its new IND application for simufilam in TSC-related epilepsy.

Next Steps

• Initiate a proof-of-concept clinical study of simufilam in TSC-related epilepsy in the first half of 2026.
• Continue exploratory preclinical studies in collaboration with the Tuberous Sclerosis Alliance (TSCA) and other researchers to better understand simufilam's potential as a treatment for TSC-related seizures.
• Present data and analyses from the positive preclinical study of simufilam in TSC-related epilepsy at an upcoming scientific conference and publication.
• Explore potential artificial intelligence (AI) capabilities and related data analytics to target improvements in productivity, efficiency, research and development activities, and statistical analysis capabilities.
• Defend all pending shareholder derivative actions and securities class actions vigorously.
• Potentially seek additional funding through public or private financing in the future.

Key Dates

Recommendation

Cassava Sciences is in a transitional phase, having discontinued its primary Alzheimer's program after Phase 3 failures and pivoting to a new, early-stage focus on TSC-related epilepsy. While the resolution of the SEC investigation and the dismissal of the indictment against a key collaborator are positive developments that reduce legal and reputational risks, significant legal liabilities from ongoing class action lawsuits remain, evidenced by the $31.25 million loss contingency. The company continues to incur net losses, and while R&D expenses have decreased, the new epilepsy program is still in preclinical/IND stage, with a proof-of-concept trial expected in H1 2026. The cash position is adequate for the next 12 months, but future capital raises are anticipated. Given the high-risk nature of clinical-stage biotech, the major setback in its previous lead program, and the very early stage of its new strategic direction, a 'Hold' recommendation is appropriate. Investors should await further clinical data, clarity on the new program's progress, and the resolution of remaining legal challenges before considering a stronger investment position.

Keywords

Biotechnology, Clinical-stage, Tuberous Sclerosis Complex, TSC-related epilepsy, Simufilam, Neurodegeneration, Neuroinflammation, Drug development, SEC filing, 10-Q, Financial results, Clinical trials, Patent, Intellectual property, Legal proceedings, Alzheimer's disease, SavaDx, Workforce reduction, Yale University